CD4+CD25+ regulatory T cell therapy for the induction of donor-specific clinical transplantation tolerance

被引:7
作者
Jiang, Shuiping [1 ]
Lechler, Robert I. [1 ]
He, Xiao-Shun [1 ]
Huang, Jie-Fu [1 ]
机构
[1] Kings Coll London, Guys Hosp, Dept Nephrol & Transplantat, London SE1 9RT, England
关键词
adoptive cell therapy; CD4(+)CD25(+) regulatory T cells; FoxP3; indirect allospecificty; individualised medicine; transplantation tolerance;
D O I
10.1517/14712598.6.10.1003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) have been shown to play a key role in the control of autoimmunity. Interestingly, they are also capable of mediating transplantation tolerance and they can have indirect allospecificity for donor antigens. An increasing body of evidence in experimental studies has indicated that adoptive transfer of in vitro expanded CD4(+)CD25(+) Tregs with indirect antidonor allospecificity can induce long-term donor-specific transplantation tolerance. Thus, adoptive cell therapy using patient-specific CD4(+)CD25(+) Tregs as individualised medicine to promote clinical transplantation tolerance is promising.
引用
收藏
页码:1003 / 1009
页数:7
相关论文
共 82 条
[1]   Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation [J].
Albert, MH ;
Liu, Y ;
Anasetti, C ;
Yu, XZ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (09) :2598-2607
[2]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[3]   Essential role for interleukin-2 for CD4+CD25+ T regulatory cell development during the neonatal period [J].
Bayer, AL ;
Yu, AX ;
Adeegbe, D ;
Malek, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (05) :769-777
[4]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[5]   Regulatory T-cell therapy: is it ready for the clinic? [J].
Bluestone, JA .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :343-349
[6]   An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+ CD25+ regulatory T cells [J].
Brusko, TM ;
Wasserfall, CH ;
Agarwal, A ;
Kapturczak, MH ;
Atkinson, MA .
JOURNAL OF IMMUNOLOGY, 2005, 174 (09) :5181-5186
[7]   Regulatory T cells, derived from naive CD4+ CD25- T cells by in vitro foxp3 gene transfer, can induce transplantation tolerance [J].
Chai, JG ;
Xue, SA ;
Coe, D ;
Addey, C ;
Bartok, I ;
Scott, D ;
Simpson, E ;
Stauss, HJ ;
Hori, S ;
Sakaguchi, S ;
Dyson, J .
TRANSPLANTATION, 2005, 79 (10) :1310-1316
[8]   Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts [J].
Ciubotariu, R ;
Liu, ZR ;
Colovai, AI ;
Ho, E ;
Itescu, S ;
Ravalli, S ;
Hardy, MA ;
Cortesini, R ;
Rose, EA ;
Suciu-Foca, N .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :398-405
[9]   Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells [J].
Coenen, JJA ;
Koenen, HJPM ;
van Rijssen, E ;
Hilbrands, LB ;
Joosten, I .
BLOOD, 2006, 107 (03) :1018-1023
[10]   Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling [J].
D'Cruz, LM ;
Klein, L .
NATURE IMMUNOLOGY, 2005, 6 (11) :1152-1159